JP2020523309A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523309A5
JP2020523309A5 JP2019567341A JP2019567341A JP2020523309A5 JP 2020523309 A5 JP2020523309 A5 JP 2020523309A5 JP 2019567341 A JP2019567341 A JP 2019567341A JP 2019567341 A JP2019567341 A JP 2019567341A JP 2020523309 A5 JP2020523309 A5 JP 2020523309A5
Authority
JP
Japan
Prior art keywords
pyrimidine
pyrazolo
carbonitrile
dihydro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523309A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/036172 external-priority patent/WO2018226771A1/en
Publication of JP2020523309A publication Critical patent/JP2020523309A/ja
Publication of JP2020523309A5 publication Critical patent/JP2020523309A5/ja
Pending legal-status Critical Current

Links

JP2019567341A 2017-06-08 2018-06-06 ピラゾロピリミジンpde9インヒビター Pending JP2020523309A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762516903P 2017-06-08 2017-06-08
US62/516,903 2017-06-08
US201862665840P 2018-05-02 2018-05-02
US62/665,840 2018-05-02
PCT/US2018/036172 WO2018226771A1 (en) 2017-06-08 2018-06-06 Pyrazolopyrimidine pde9 inhibitors

Publications (2)

Publication Number Publication Date
JP2020523309A JP2020523309A (ja) 2020-08-06
JP2020523309A5 true JP2020523309A5 (enExample) 2021-07-26

Family

ID=62779024

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567341A Pending JP2020523309A (ja) 2017-06-08 2018-06-06 ピラゾロピリミジンpde9インヒビター

Country Status (13)

Country Link
US (2) US10934294B2 (enExample)
EP (1) EP3634964B1 (enExample)
JP (1) JP2020523309A (enExample)
KR (1) KR20200013758A (enExample)
CN (1) CN111051308A (enExample)
AU (1) AU2018281131B2 (enExample)
BR (1) BR112019025813A2 (enExample)
CA (1) CA3064938A1 (enExample)
MA (1) MA53841A (enExample)
MX (1) MX2019014597A (enExample)
RU (1) RU2019144010A (enExample)
TW (1) TW201902898A (enExample)
WO (1) WO2018226771A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934294B2 (en) * 2017-06-08 2021-03-02 Merck Sharp & Dohme Corp. Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors
WO2020123271A1 (en) * 2018-12-12 2020-06-18 Merck Sharp & Dohme Corp. Cyclobutyl pyrazolopyrimidine pde9 inhibitors
WO2020123272A1 (en) * 2018-12-12 2020-06-18 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors
AU2020235187B8 (en) * 2019-03-08 2024-02-08 Transthera Sciences (Nanjing), Inc. Uses of phosphodiesterase inhibitors
WO2021253180A1 (en) * 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
CN114773256B (zh) * 2022-03-23 2024-05-03 中国农业大学 一种4-氰基哌啶的合成方法
CN117582909B (zh) * 2024-01-19 2024-04-02 天津凯莱英医药科技发展有限公司 一种连续生产5-单硝酸异山梨酯的系统和方法
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE71183B1 (en) 1988-12-27 1997-01-29 Takeda Chemical Industries Ltd Guanidine derivatives their production and insecticides
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
ES2233685T3 (es) 2000-08-01 2005-06-16 Bayer Healthcare Ag Inhibidores selectivos de pde 2 como medicamentos para mejorar la percepcion.
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
HUP0401998A2 (hu) 2001-11-02 2005-01-28 Pfizer Products Inc., PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
US8293754B2 (en) 2005-06-14 2012-10-23 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
CA2914168C (en) 2006-03-28 2018-05-08 Atir Holding S.A. Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders
US8101624B2 (en) 2006-08-08 2012-01-24 Aska Pharmaceutical Co., Ltd. Quinazoline derivatives
KR101563103B1 (ko) 2006-12-13 2015-10-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
AU2008249750B2 (en) 2007-05-11 2011-07-14 Pfizer Inc. Amino-heterocyclic compounds
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びcns障害の治療のためのそれらの使用
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
TW201118099A (en) 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
NZ603725A (en) * 2010-08-12 2015-04-24 Boehringer Ingelheim Int 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2906562B1 (en) 2011-10-10 2016-10-05 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
KR101706216B1 (ko) 2012-04-03 2017-02-13 한화테크윈 주식회사 고밀도 삼차원 영상 재구성 장치 및 방법
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
US10376504B2 (en) 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
WO2017019724A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone pde9 inhibitors
WO2017019726A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Oxy-cyanoquinolinone pde9 inhibitors
US10934294B2 (en) * 2017-06-08 2021-03-02 Merck Sharp & Dohme Corp. Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors

Similar Documents

Publication Publication Date Title
JP2020523309A5 (enExample)
JP6461263B2 (ja) C−fmsおよび/またはc−kit活性を調節する化合物およびその用途
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
US8685993B2 (en) Bi-heteroaryl compounds as Vps34 inhibitors
CA2515197A1 (en) Pyrazolopyridine derivates
TWI672292B (zh) 作為pde4抑制劑之經取代之吡啶及吡化合物
JP2018524331A5 (enExample)
ME02802B (me) P2x7 modulatori
HRP20160326T1 (hr) Derivati piperidin-4-il azetidina kao inhibitori jak1
JP2013523884A5 (enExample)
JP2018118992A5 (enExample)
JP2018109013A (ja) キナーゼ調節のための化合物および方法、ならびにその適応
HRP20160539T1 (hr) Antagonisti trpv4
JP2016523911A5 (enExample)
JP2014531465A5 (enExample)
JP2013522214A5 (enExample)
JP2017528519A5 (enExample)
JP2014528446A5 (enExample)
JP2014518214A5 (enExample)
RU2019144010A (ru) Пиразолопиримидиновые ингибиторы pde9
JP2020502230A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2018508553A5 (enExample)
RU2020114670A (ru) Бициклические соединения для применения в качестве ингибиторов rip1 киназы
RU2018105872A (ru) Этинильные производные